CALT Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 12:33):

Stats
Today's Volume	4 404.00
Average Volume	7 832.00
Market Cap	498.48M
EPS	$0 ( 2024-02-21 )
Next earnings date	( $-0.140 ) 2024-05-21
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-11.61
ATR14	$0.212 (1.14%)

Calliditas Therapeutics Correlation

10 Most Positive Correlations
BLPH	0.931
ASLN	0.922
ORTX	0.916
KBAL	0.908
UNCY	0.902
ADMS	0.888
ALBO	0.887
PLPC	0.884
CMPI	0.879
CPTA	0.877

10 Most Negative Correlations
CARA	-0.92
STIM	-0.908
ACNB	-0.906
VEON	-0.902
TVACW	-0.899
CPTN	-0.899
ALEC	-0.898
PCB	-0.896
CBAN	-0.895
BRKL	-0.893

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Calliditas Therapeutics Financials

Annual	2023
Revenue:	$1.21B
Gross Profit:	$1.15B (94.99 %)
EPS:	$-8.69

Q4	2023
Revenue:	$451.56M
Gross Profit:	$429.26M (95.06 %)
EPS:	$-0.340

Q3	2023
Revenue:	$294.59M
Gross Profit:	$279.67M (94.94 %)
EPS:	$-3.14

Q2	2023
Revenue:	$269.38M
Gross Profit:	$255.17M (94.72 %)
EPS:	$-1.710

Financial Reports:

No articles found.

Calliditas Therapeutics

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.